[12] Patent
[11] Patent No.:GC0009282  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/140795
Date of the Decision to Grant the Patent:04/Dec/2018

[21] Application No.:GC 2015-29667

[22] Filing Date:2/7/2015

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
2/7/2014
29/5/2015
62/020,166
62/168,627

[72] Inventors:1- Christopher Michael Adams،2- Doug Bevan،3- Michael Paul Capparelli،4- Takeru Ehara،5- Luciana Ferrara،6- Nan Ji،7- Erik Meredith،8- Muneto Mogi،9- James J. Powers،10- Ganesh Prasanna،11- Nello Mainolfi،12- Mitsunori Kato

[73] Owner: Novartis AG, Lichtstrasse 35 4056, Basel , Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.: A61K 31/445; A61P 27/06; C07D 401/10, 401/12, 401/14 (2006.01)

[56] Cited Documents:

-WO 2008073452 A1 (REVIVA PHARMACEUTICALS INC?[US MOHAPATRA PRABHU PRASAD?[US]) 19 June 2008
-WO 2010099054 A2 (MERCK SHARP & DOHME?[US] KIM RONALD M?[US]) 02 September 2010
 
Examiner: PH. Neda J. AlMuallem

[54] INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
[57] Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
No. of claims: 22


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.